CURRICULUM VITAE FORMAT University of Pittsburgh School of Medicine BIOGRAPHICAL Name: Andreas Vogt Birth Date: Nov 15, 1959 Home Address: 5626 Callowhill Street Birth Place: Hamburg, Germany Home Phone: 412 441 5654 Citizenship: German Business Address: UPDDI, BST-3 10047 E-Mail Address: avogt@pitt.edu Business Phone: 412 383 5856 Business Fax: 412 648 9009 _________________________________________________________________________________ EDUCATION and TRAINING List entries in each section chronologically UNDERGRADUATE: Dates Attended Name and Location Degree Received Major Subject of Institution and Year 1980 – 1984 University of Hamburg,

Germany M.S., 1985 Pharmacy GRADUATE: Dates Attended Name and Location Degree Received Major Advisor of Institution and Year and Discipline

1985 – 1990 University of Hamburg Ph.D., 1990 Dieter Matthies

Pharmaceutical Chemistry POSTGRADUATE: Include internships, residencies, fellowships and/or any other professional training experience Dates Attended Name and Location Name of Program Director of Institution and Discipline 1990 - 1993 University of Kentucky

Lexington Donald F. Diedrich

Pharmacology

Curriculum Vitae Name and Title

Revision Date Page 2

APPOINTMENTS and POSITIONS ACADEMIC: Years Inclusive Name and Location Rank/Title 1994 - 1996 University of Pittsburgh

Dept. Pharmacology Research Associate

1996 – 2011 University of Pittsburgh Dept. Pharmacology and Chemical Biology

Research Assistant Professor

2011 – 2012 University of Pittsburgh Dept. Computational and Systems Biology

Research Assistant Professor

2012 – present University of Pittsburgh Dept. Computational and Systems Biology

Associate Professor

NON-ACADEMIC: Include military or other Government service Years Inclusive Name and Location Rank/Title of Institution or of Organization Position 1985 - 1989 Public Pharmacies

Germany Pharmacist

1996 - 1999 ProlX Pharmaceuticals Pittsburgh (now Oncothyreon, Inc.)

Scientific Director

Curriculum Vitae Name and Title

Revision Date Page 3

_________________________________________________________________________________ CERTIFICATION and LICENSURE SPECIALTY CERTIFICATION: Certifying Board Year

MEDICAL or OTHER PROFESSIONAL LICENSURE: Licensing Board/State Year Pharmacy License, Germany 1985

_________________________________________________________________________________ MEMBERSHIPS in PROFESSIONAL and SCIENTIFIC SOCIETIES

Organization Year American Association for Cancer Research American Chemical Society Deutsche Pharmazeutische Gesellschaft Licensing Executives Society Society of Biomolecular Screening

1994 - current 1992 - current 1995 - current 1999-2003 2002 - current

_________________________________________________________________________________ HONORS Title of Award Year Young Investigator Award, AACR annual meeting, Toronto

1995

_________________________________________________________________________________

Curriculum Vitae Name and Title

Revision Date Page 4

PUBLICATIONS 1. Refereed articles

* senior or corresponding author 1. Matthies D, Siewers S, Vogt A. Reaktive Eigenschaften der C-Aryl-Glycin-Struktur: Synthese und

Eigenschaften von Acylierungsprodukten des 3-Acylamino-5-methyl- 2(3H)-benzofuranons. Chemiker-Zeitung. 1990;114:283-7.

2. Qian Y, Blaskovich MA, Seong CM, Vogt A, Hamilton AD, Sebti SM. Peptidomimetic inhibitors of p21 Ras farnesyltransferase: hydrophobic functionalization leads to disruption of p21 Ras membrane association in whole cells. BioorgMedChemLett. 1994;4(21):2579-84.

3. McGuire TF, Qian Y, Blaskovich MA, Fossum RD, Sun J, Marlowe T, Corey SJ, Wathen SP, Vogt A, Hamilton AD, Sebti SM. CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase. BiochemBiophysResComm. 1995;214(1):295-303. PMID: 7669049

4. Vogt A, Qian Y, Blaskovich MA, Fossum RD, Hamilton AD, Sebti SM. A non-peptide mimetic of Ras-CAAX: Selective inhibition of farnesyltransferase and Ras processing. J Biol Chem. 1995;270(2):660-4. PMID: 7822292

5. Kauffmann RC, Qian Y, Vogt A, Sebti SM, Hamilton AD, Carthew RW. Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors. Proc Natl Acad Sci U S A. 1995;92:10919-23. PMID: 7479910

6. Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD, Sebti SM. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras/Raf complexes. J Biol Chem. 1995;270(45):26802-6. PMID: 7592920

7. Vogt A, Sun J, Qian Y, Tan-Chiu E, Hamilton AD, Sebti SM. Burkitt lymphoma Daudi cells contain two distinct farnesyltransferases with different divalent cation requirements. Biochemistry. 1995;34:12398-403.PMID: 7547984

8. Qian Y, Vogt A, Sebti SM, Hamilton AD. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors. J Med Chem. 1996;39:217-23. PMID: 8568811

9. McGuire TF, Qian Y, Vogt A, Hamilton AD, Sebti SM. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. J Biol Chem. 1996;271(44):27402-7. PMID: 8910319

10. Vogt A, Qian Y, McGuire TF, Hamilton AD, Sebti SM. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene. 1996;13(9):1991-9. PMID: 8934546

11. Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem. 1997;272(43):27224-9. PMID: 9341167

12. Qian Y, Vogt A, Vasudevan A, Sebti SM, Hamilton AD. Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics. Bioorg Med Chem. 1998;6(3):293-9. PMID: 9568283

13. Vogt A, Rice RL, Settineri CE, Yokokawa F, Yokokawa S, Wipf P, Lazo JS. Disruption of insulin-like growth factor-1 signaling and down- regulation of cdc2 by SC-ααδ9, a novel small molecule antisignaling agent identified in a targeted array library. JPharmacolExpTher. 1998;287:806-13.PMID: 9808713

14. Qian Y, Marugan JJ, Fossum RD, Vogt A, Sebti SM, Hamilton AD. Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors. Bioorg Med Chem. 1999;7(12):3011-24. PMID: 10658608

15. Vasudevan A, Qian Y, Vogt A, Blaskovich MA, Ohkanda J, Sebti SM, Hamilton AD. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. J Med Chem. 1999;42(8):1333-40. PMID: 10212118

Curriculum Vitae Name and Title

Revision Date Page 5

16. Vogt A, Wang AS, Johnson CS, Fabisiak JP, Wipf P, Lazo JS. In vivo antitumor activity and induction of insulin-like growth factor- 1-resistant apoptosis by SC-alpha-alpha-delta9. J Pharmacol Exp Ther. 2000;292(2):530-7. PMID: 10640289

17. Vogt A, Tamura K, Watson S, Lazo JS. Antitumor imidazolyl disulfide IV-2 causes irreversible G(2)/M cell cycle arrest without hyperphosphorylation of cyclin-dependent kinase Cdk1. JPharmacolExpTher. 2000;294(3):1070-5. PMID: 10945861

18. Lazo JS, Tamura K, Vogt A, Jung JK, Rodriguez S, Balachandran R, Day BW, Wipf P. Antimitotic actions of a novel analog of the fungal metabolite palmarumycin CP1. J Pharmacol Exp Ther. 2001;296(2):364-71. PMID: 11160619

19. Lazo JS, Aslan DC, Southwick EC, Cooley KA, Ducruet AP, Joo B, Vogt A, Wipf P. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J Med Chem. 2001;44(24):4042-9. PMID: 11160619

20. Vogt A, Adachi T, Ducruet AP, Chesebrough J, Nemoto K, Carr BI, Lazo JS. Spatial analysis of key signaling proteins by high-content solid-phase cytometry in Hep3B cells treated with an inhibitor of Cdc25 dual-specificity phosphatases. J Biol Chem. 2001;276(23):20544-50. PubMed PMID: 11274178

21. Vogt A, Pestell KE, Day BW, Lazo JS, Wipf P. The antisignaling agent SC-alpha alpha delta 9, 4-(benzyl-(2-[(2,5- diphenyloxazole-4-carbonyl)amino]ethyl)carbamoyl)- 2- decanoylaminobutyric acid, is a structurally unique phospholipid analogue with phospholipase C inhibitory activity. Mol Cancer Ther. 2002;1(11):885-92. (cover issue) PMID: 12481409

22. Vogt A, Cooley KA, Brisson M, Tarpley MG, Wipf P, Lazo JS. Cell-active dual specificity phosphatase inhibitors identified by high-content screening. Chem Biol. 2003;10(8):733-42.PMID: 12954332

23. Nemoto K, Vogt A, Oguri T, Lazo JS. Activation of the Raf-1/MEK/Erk kinase pathway by a novel Cdc25 inhibitor in human prostate cancer cells. Prostate. 2004;58(1):95-102. PMID: 14673957

24. Brisson M, Nguyen T, Vogt A, Yalowich J, Giorgianni A, Tobi D, Bahar I, Stephenson CR, Wipf P, Lazo JS. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase. Mol Pharmacol. 2004;66(4):824-33. PMID: 15231869

25. Vogt A, Kalb EN, Lazo JS. A scalable high-content cytotoxicity assay insensitive to changes in mitochondrial metabolic activity. Oncol Res. 2004;14(6):305-14. PMID: 15206493

26. Ducruet AP, Vogt A, Wipf P, Lazo JS. Dual specificity protein phosphatases: Therapeutic targets for cancer and alzheimer's disease. Annu Rev Pharmacol Toxicol. 2005;45:725-50. PMID: 15822194

27. Vogt A, Lazo JS. Chemical complementation: A definitive phenotypic strategy for identifying small molecule inhibitors of elusive cellular targets. Pharmacol Ther. 2005;107:212-5. PMID: 15925410

28. Madiraju C, Edler MC, Hamel E, Raccor BS, Balachandran R, Zhu G, Giuliano KA, Vogt A, Shin Y, Fournier JH, Fukui Y, Bruckner AM, Curran DP, Day BW. Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin. Biochemistry. 2005;44(45):15053-63. PMID: 16274252

29. Vogt A, Tamewitz A, Skoko J, Sikorski RP, Giuliano KA, Lazo JS. The benzo (c) phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J Biol Chem. 2005;280(19):19078-86.PMID: 15753082

30. Ohkanda J, Strickland CL, Blaskovich MA, Carrico D, Lockman JW, Vogt A, Bucher CJ, Sun J, Qian Y, Knowles D, Pusateri EE, Sebti SM, Hamilton AD. Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. Organic & Biomolecular Chemistry. 2006;4(3):482-92. PMID: 16446806

31. Wipf P, Graham TH, Vogt A, Sikorski RP, Ducruet AP, Lazo JS. Cellular analysis of disorazole C1 and structure-activity relationship of analogs of the natural product. Chem Biol Drug Des. 2006;67:66-73. PMID: 16492150

32. Lazo JS, Nunes R, Skoko JJ, de Oliveira PE, Vogt A, Wipf P. Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1. Bioorg Med Chem. 2006;14(16):5643-50. PMID: 16698271

Curriculum Vitae Name and Title

Revision Date Page 6

33. Shin Y, Fournier JH, Bruckner A, Madiraju C, Balachandran R, Raccor BS, Edler MC, Hamel E, Sikorski RP, Vogt A, Day BW, Curran DP. Synthesis and biological evaluation of (-)-dictyostatin and stereoisomers. Tetrahedron. 2007;63(35):8537-62. PMCID: PMC2000856.

34. Jung WH, Harrison C, Shin Y, Fournier JH, Balachandran R, Raccor BS, Sikorski RP, Vogt A, Curran DP, Day BW. Total synthesis and biological evaluation of C16 analogs of (-)-dictyostatin. J Med Chem. 2007;50(13):2951-66. PMID: 17542572

35. Wang Z, McPherson PA, Raccor BS, Balachandran R, Zhu G, Day BW, Vogt A, Wipf P. Structure-activity and high-content imaging analyses of novel tubulysins. Chem Biol Drug Des. 2007;70(2):75-86. (cover issue) PMID: 17683369

36. Vogt A, Lazo JS. Implementation of high-content assay for inhibitors of mitogen-activated protein kinase phosphatases. Methods. 2007;42(3):268-77. PMCID: PMC1950282.

37. Raccor BS, Vogt A, Sikorski RP, Madiraju C, Balachandran R, Montgomery K, Shin Y, Fukui Y, Jung WH, Curran DP, Day BW. Cell-based and biochemical structure-activity analyses of analogs of the microtubule stabilizer dictyostatin. Mol Pharmacol. 2008;73(3):718-26. (cover issue) PMID: 18073274

38. Vogt A, McDonald PR, Tamewitz A, Sikorski RP, Wipf P, Skoko JJ, 3rd, Lazo JS. A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol Cancer Ther. 2008;7(2):330-40. PMID: 18245669

39. Zou H, Thomas SM, Yan ZW, Grandis JR, Vogt A, Li LY. Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells. FASEB Journal. 2009;23(2):425-32. PMCID: PMC2638965.

40. Albert BJ, McPherson PA, O'Brien K, Czaicki NL, Destefino V, Osman S, Li M, Day BW, Grabowski PJ, Moore MJ, Vogt A, Koide K. Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. Mol Cancer Ther. 2009;8(8):2308-18. PMCID: PMC2762647.

41. Vogt A, Cholewinski A, Shen X, Nelson SG, Lazo JS, Tsang M, Hukriede NA. Automated image-based phenotypic analysis in zebrafish embryos. Dev Dyn. 2009;238(3):656-63. PMCID: PMC2861575.

42. Vogt A, McPherson PA, Shen X, Balachandran R, Zhu G, Raccor BS, Nelson SG, Tsang M, Day BW. High-content analysis of cancer-cell-specific apoptosis and inhibition of in vivo angiogenesis by synthetic (-)-pironetin and analogs. Chem Biol Drug Des. 2009;74(4):358-68. PMCID: PMC2963022.

43. Molina G#, Vogt A#, Bakan A#, Dai W, de Oliveira PQ, Znosko W, Smithgall TE, Bahar I, Lazo JS, Day BW, Tsang M. Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol. 2009;6(8):680-7. PMCID: PMC2771339. (# equal contribution) PMCID: PMC2771339

44. Lazo JS, Reese CE, Vogt A, Vollmer LL, Kitchens CA, Gunther E, Graham TH, Hopkins CD, Wipf P. Identifying a resistance determinant for the antimitotic natural products disorazole C1 and A1. J Pharmacol Exp Ther. 2010;332(3):906-11. PMCID: PMC2835430.

45. Zhu W, Jimenez M, Jung WH, Camarco DP, Balachandran R, Vogt A, Day BW, Curran DP. Streamlined syntheses of (-)-dictyostatin, 16-desmethyl-25,26-dihydrodictyostatin, and 6-epi-16-desmethyl-25,26-dihydrodictyostatin. J Am Chem Soc. 2010;132(26):9175-87. PMCID: PMC2903049.

46. Vogt A, Codore H, Day BW, Hukriede NA, Tsang M. Development of automated imaging and analysis for zebrafish chemical screens. J Vis Exp. 2010;40. PMCID: PMC3149986. http://www.jove.com/index/details.stp?id=1900, doi: 10.3791/1900

47. Vollmer LL, Jimenez M, Camarco DP, Zhu W, Daghestani HN, Balachandran R, Reese CE, Lazo JS, Hukriede NA, Curran DP, Day BW, Vogt A. A Simplified Synthesis of Novel Dictyostatin Analogues with In Vitro Activity against Epothilone B-Resistant Cells and Antiangiogenic Activity in Zebrafish Embryos. Mol Cancer Ther. 2011;10(6):994-1006. PMCID: 3112307.

48. Saydmohammed M, Vollmer LL, Onuoha EO, Vogt A, Tsang M. A high-content screening assay in transgenic zebrafish identifies two novel activators of fgf signaling. Birth Defects Res C Embryo Today. 2011;93(3):281-7. PMID: 21932436 PMCID: PMC-Journal in Process.

49. Jimenez M, Zhu W, Vogt A, Day BW, Curran DP. Efficient syntheses of 25,26-dihydrodictyostatin and 25,26-dihydro-6-epi-dictyostatin, two potent new microtubule-stabilizing agents. Beilstein J Org Chem. 2011;7:1372-8. PMCID: 3201051.

Curriculum Vitae Name and Title

Revision Date Page 7

50. Farrell TC, Cario CL, Milanese C, Vogt A, Jeong JH, Burton EA. Evaluation of spontaneous propulsive movement as a screening tool to detect rescue of Parkinsonism phenotypes in zebrafish models. Neurobiol Dis. 2011;44(1):9-18. (cover issue) PMCID: 3153634.

51. Li M, Chen X, Ye QZ, Vogt A, Yin XM. A high-throughput FRET-based assay for determination of Atg4 activity. Autophagy. 2012;8(3). PMCID: 3337841

52. Soares MA, Lessa JA, Mendes IC, Da Silva JG, Dos Santos RG, Salum LB, Daghestani H, Andricopulo AD, Day BW, Vogt A, Pesquero JL, Rocha WR, Beraldo H. N(4)-Phenyl-substituted 2-acetylpyridine thiosemicarbazones: cytotoxicity against human tumor cells, structure-activity relationship studies and investigation on the mechanism of action. Bioorg Med Chem. 2012;20(11):3396-409. PMID: 22564383

53. Arora R, Shuda M, Guastafierro A, Feng H, Toptan T, Tolstov Y, Normolle D, Vollmer LL, Vogt A, Domling A, Brodsky JL, Chang Y, Moore PS. Survivin is a therapeutic target in Merkel cell carcinoma. Sci Transl Med. 2012;4(133):133ra56. PMCID: PMC 3726222

http://stm.sciencemag.org/content/4/133/133ra56.full.pdf 54. Sehrawat, A., Kim, S.-H., Vogt, A., and Singh, S.V. (2012) Suppression of FOXQ1 in benzyl

isothiocyanate-mediated inhibition of epithelial-mesenchymal transition in human breast cancer cells Carcinogenesis 2013;34(4):864-873 PMID: 23276794 PMCID: PMC3616667

55. Lessa JA, Soares MA, Dos Santos RG, Mendes IC, Salum LB, Daghestani HN, Andricopulo AD, Day BW, Vogt A, Beraldo H. Gallium(III) complexes with 2-acetylpyridine-derived thiosemicarbazones: antimicrobial and cytotoxic effects and investigation on the interactions with tubulin. Biometals. 2013;26(1):151-65. PMID: 23344786 PMCID: PMC-Journal in Process

56. Salum LB, Altei WF, Chiaradia LD, Cordeiro MN, Canevarolo RR, Melo CP, Winter E, Mattei B, Daghestani HN, Santos-Silva MC, Creczynski-Pasa TB, Yunes RA, Yunes JA, Andricopulo AD, Day BW, Nunes RJ, Vogt A. Cytotoxic 3,4,5-trimethoxychalcones as mitotic arresters and cell migration inhibitors. Eur J Med Chem. 2013;63:501-10. PMID: 23524161 PMCID: PMC3674157

57. Gao Y, Vogt A, Forsyth CJ, Koide K. Comparison of splicing factor 3b inhibitors in human cells. Chembiochem. 2013;14(1):49-52. PMID: 23172726; PMCID: PMC-Journal in Process.

58. Li M, Khambu B, Zhang H, Kang JH, Chen X, Chen D, Vollmer L, Liu PQ, Vogt A, Yin XM. Suppression of lysosome function induces autophagy via a feedback down-regulation of MTOR complex 1 (MTORC1) activity. J Biol Chem. 2013;288(50):35769-80. PMID: 24174532; PMCID: PMC3861628.

59. Sanker S, Cirio MC, Vollmer LL, Goldberg ND, McDermott LA, Hukriede NA, Vogt A. Development of high-content assays for kidney progenitor cell expansion in transgenic zebrafish. J Biomol Screen. 2013;18(10):1193-202. PMID: 23832868; PMCID: PMC3830658.

Featured in Special Issue: Phenotypic Drug Discovery http://jbx.sagepub.com/content/18/10/1193.full 60. Poe JA, Vollmer L, Vogt A, Smithgall TE. Development and validation of a high-content bimolecular

fluorescence complementation assay for small-molecule inhibitors of HIV-1 Nef dimerization. J Biomol Screen. 2014;19(4):556-65. PMID: 24282155; PMCID: PMC4006692.

61. Joy ME, Vollmer, LL, Hulkower, KI, Stern, AM, Roy, P, Vogt A. (2014) A high content, multiplexed screen in human breast cancer cells identifies profilin-1 inducers with anti-migratory activities. PLoS ONE 9(2): e88350. doi:10.1371/journal.pone.0088350 PMCID: 3919756

62. Korotchenko, VN, Saydmohammed M, Vollmer LL, Bakan A, Sheetz K, Debiec KT, Greene KA, Agliori, CS, Bahar I, Day BW., Vogt A, Tsang M. In Vivo Structure-Activity Relationship Studies Support Allosteric Targeting of a Dual Specificity Phosphatase. Chembiochem 15(10): 1436-1445 (2014). PMCID: PMC4118675

2. Reviews, invited published papers, proceedings of conference and symposia,

monographs, books and book chapters 1. Vogt A. Advances in two-dimensional cell migration technologies. Eur Pharm Rev. 2010;15(5):26-9. 2. Vogt A, Lazo JS. An unusual case of self-defense. Cell Cycle News and Views. 2009;8(21):3452.

http://www.landesbioscience.com/journals/cc/03-CCNewsViews8-21.pdf

Curriculum Vitae Name and Title

Revision Date Page 8

3. Vogt A, Tsang M, Hukriede NA. Artificial Intelligence-Based Analysis of Whole Organism Images. American Biotechnology Laboratory. 2009;27(10):10-2.

4. Vogt A, Lazo JS. Discovery of protein kinase phosphatase inhibitors. in: High Content Screening – A Powerful Approach to Systems Cell Biology and Drug Discovery (Giuliano, K, Taylor, D.L., and Haskins, J.R., eds.). Methods Mol Biol. 2006;356:389-400. PMID: 17532514

3. Published abstracts 1. Vollmer, L., Vernetti, L., Bakan, A., Korotchenko, V.N., Bahar, I., Day, B.W., Tsang, M, and Vogt, A. A

non-redox reactive allosteric inhibitor of MAPK phosphatases with selective toxicity to human cancer cells. AACR Annual Meeting, San Diego, CA (2014)

2. Fronczak, J.A., Gajeski, M.S.,, Erica L. Beckman, E.L., Vollmer, L., Vogt, A., and Krishnan, G. A 3-Dimensional Cell Invasion Assay Compatible with High Content Screening AACR Annual Meeting, San Diego, CA (2014)

3. Ding, Z., Joy, M., Vollmer, L., Stern, A, Vogt, A., and Roy, P. Genetic and pharmacological proof-of-concept studies imply profilin-1 as a potential target for blocking metastatic colonization of breast cancer cells AACR Annual Meeting, San Diego, CA (2014)

4. Fronczak, J., Vollmer, L., Krishnan, G., and Vogt, A. HTS Performance and High‐content Analysis of Antimigratory Compound Phenotypes Using the Oris™ Pro 384 Cell Migration Assay. AACR annual meeting, Washington, DC 2013

5. Sehrawat, A., Kim, S.-H., Vogt, A., and Singh, S.V. Suppression of FOXQ1 in benzyl isothiocyanate-mediated inhibition of epithelial-mesenchymal transition in human breast cancer cells. AACR annual meeting, Washington, DC 2013

6. Zajc, B. Kumar, R., Salum, L. B., Vogt, A., and Day, B. Triazole-Derived Combretastatin A-4 Analogs, 13th RCMI International Symposium on Health Disparities, San Juan, Puerto Rico, December 2012.

7. Fronczak, J., Vollmer, L.., Krishnan, G., and Vogt, A., High Throughput Screening Assay Development and Performance of the Oris™ Pro 384 Cell Migration Assay Cell Symposia – Hallmarks of Cancer October 29-31, San Francisco (2012)

8. Moore, P. S., Arora, R., Shuda, M., Guastafierro, A., Feng, H., Toptan, T., Tolstov, Y., Normolle, D., Vollmer, L.L., Vogt, A., Doemling, A., Brodsky, J., and Chang, Y. Rapid rational drug targeting of Merkel cell polyomavirus (MCV)-positive Merkel cell carcinoma (MCC) using the survivin inhibitor YM155 American Society for Clinical Oncology (ASCO) Chicago, IL (2012) Abstract #99341

9. Fronczak, J, Finer, J., Gehler, S., Hulkower, K, and Vogt, A.. A robust 384-well cell migration assay for high-content analysis. AACR annual meeting, Washington, DC (2011).

10. Smith, B, Vogt, A., Nakashima, M., and Hulkower, K. I., Substrate Dependent Effects of c-Met Inhibitors on HGF-induced Cell Migration. American Society for Cell Biology, San Francisco, CA (2008)

11. Vogt, A., Automated analysis of transgenic fluorescent zebrafish embryos by Cognition Network Technology. 8th International Meeting on Zebrafish Development & Genetics, Madison, WI (2008)

12. Smith, B, Vogt, A., Nakashima, M., and Hulkower, K. I., Substrate Dependent Effects of c-Met Inhibitors on HGF-induced Cell Migration. American Society for Cell Biology, San Francisco, CA 2008

13. Vogt,A., McPherson, P.A., Balachandran, R., Day, B.W., Shen, X., and Nelson, S.G. Synthetic (−)-pironetins cause cancer cell-specific apoptosis and inhibit angiogenesis in zebrafish embryos. AACR annual meeting, San Diego, CA 2008.

14. Vogt,A., McPherson, P.A., Balachandran, R., Day, B.W., Shen, X., and Nelson, S.G. High-content analysis of synthetic (-)-pironetin and its optical antipode AACR annual meeting, Los Angeles, CA 2007.

15. Vogt, A., Sikorski, R.P., Graham, T., Wipf, P., and Lazo, J.S. High Content Analysis of the Putative Microtubule Perturbing Agent Disorazole C1. EORTC annual meeting, Philadelphia, PA 2005

16. Vogt, A., Tamewitz, A., Sikorski, R.P., McDonald, P., and Lazo, J.S. A small molecule inhibitor of mitogen activated protein kinase phosphatase identified by high content screening. AACR annual meeting, Anaheim, CA 2005

17. Madiraju, C., Edler, M.D., Giuliano, K.A., Vogt, A., Balachandran, R, aRaccor, B., Hamel, E., Shin, Y., Fournier, J.-H., Fukui, Y., Bruckner, A.M., Curran, D.P., Day, B.W. Tubulin Assembly, Paclitaxel Site

Curriculum Vitae Name and Title

Revision Date Page 9

Binding and Cellular Effects of the Microtubule-Stabilizing Agent Dictyostatin-1. AACR annual meeting, Anaheim, CA 2005

18. Madiraju, C., Edler, M.D., Giuliano, K.A., Vogt, A., Balachandran, R., Raccor, B., Hamel, E., Shin, Y., Curran, D.P., Day, B.W. Synthesis, biological evaluation and structure-activity relationship analysis of (–)-dictyostatin-1 and analogues. ACS annual meeting 2005

19. Vogt, A., McDonald, P., Walrath, N., Tamewitz, A., Lazo, J.S. A high-content chemical complementation assay for identifying cell permeable MAPK phosphatase-1 inhibitors. AACR annual meeting, Orlando, FL, 2004

20. Vogt, A., Tarpley, M.G., Cooley, K.A., Wipf, P., and Lazo, J.S. Dual specificity phosphatase inhibitors identified by high content screening of the NCI Diversity Set. AACR annual meeting, Washington, DC, 2003

21. Vogt, A., Tarpley, M. G, Cooley, K., Wipf, P., and Lazo, J. S. Identification Of Dual Specificity Phosphatase Inhibitors By A Cell-Based, High Content Screen . Proceedings of the Society for Biomolecular Screening, The Hague, NL (2002)

22. Vogt, A., Pestell, K.E., Day, B.W., Wipf, P., and Lazo, J.S., Phospholipase C as a target of the antitumor

agent, SC-9. AACR annual meeting, San Franscisco, 2002 23. Lazo, J.S., Vogt, A., Nemoto, K., Cooley, K.A., Aslan, D., and Wipf, P.W., Inhibitors of oncogenic dual-

specific phosphatases identified by cell-based high-content screening. AACR annual meeting, San Franscisco, 2002

24. Nichols. M., Kanterewicz, B., Cheng, P., Liu, Y., Vogt, A., and Day, B.W., Biochemical and cell-based analysis shows strong antiestrogenic character of dichlorocyclopropanes prepared by improved solid-phase synthesis. AACR annual meeting, San Franscisco, 2002

25. Vogt, A., Chesebrough, J., Carr, B.C., and Lazo, J.S., Quantitation of Erk and p38 activation in human hepatoma cells by high-content solid-phase cytometry AACR annual meeting, New Orleans, 2001

26. Vogt, A., Tamura, K., Heinrich, S., Southwick, E. Kirkpatrick, D.L., Powis, G., and Lazo, J.S. Inhibition of G2/M Transition by the Asymmetrical Disulfide PX-12. AACR annual meeting, San Francisco, 2000.

27. Kirkpatrick, D.L., Powis G., Hashash, A., Vogt, A., Egorin, M.J., and Lazo, J.S. PX-12 and PX-36: novel redox-regulatory drugs with antitumor activity; toxicity and pharmacokinetics. AACR annual meeting, San Francisco, 2000.

28. Powis G., Kirkpatrick, D.L., Hashash, A., Vogt, A., Egorin, M.J., and Lazo, J.S. 2-Imidazolyl disulfides (DS): A novel class of thioredoxin (Trx) reactive antitumor agents with a novel mechanism of action. EORTC/NCI meeting, Washington, DC, 1999

29. Vogt, A., Wang, A., Fabisiak, J., Wipf, P., and John S. Lazo, J.S., Induction of apoptosis in 32D cells by SC-9, a novel inhibitor of IGF-1 receptor autophosphorylation. AACR annual meeting, Philadelphia, 1999.

30. Powis, G., Grogan, T., Kirkpatrick, D.L., Lazo, J., and Vogt, A., Thioredoxin, a novel redox oncoprotein drug target for cancer therapy. EORTC annual meeting, Amsterdam, The Netherlands, 1998

31. Vogt, A., Rice, R.L., Yokokawa, F., Yokokawa, S., Wipf, P., and Lazo, J.S., Selective toxicity of the Cdc25 inhibitor SC-9 is associated with disruption of the IGF-1 receptor signaling pathway. AACR annual meeting, New Orleans, 1998.

32. Rice, R.L., Vogt, A., Johnson, C.S., Yokokawa, F., Yokokawa, S. Wipf, P. and Lazo J.S., Antiproliferative and antitumor activity of targeted combinatorial library members modeled from natural product phosphatase inhibitors. AACR annual meeting, New Orleans, 1998.

33. Vogt, A., Qian, Y., Hamilton, A.D., and Sebti, S.M, Inhibition of protein geranylgeranylation arrests human tumor cells in G1 through p53 independent induction of p21WAF1/CIP1/SDI1 AACR annual meeting, San Diego, 1997.

34. Vogt, A., Qian, Y., McGuire, T.F., Blaskovich, M.A., Hamilton, A.D., and Sebti, S.M., Selective inhibition of geranylgeranyltransferase-I, not farnesyltransferase, arrests cells in G1. AACR annual meeting, Washington, DC, 1996.

35. Lerner, E.C., Qian, Y., Blaskovich, M.A., Fossum, R.D., Vogt, A., Sun, J., Cox, A.D., Der, C.J., Hamilton, A.D. and Sebti, S.M., Accumulation of Inactive Ras/Raf Complexes in the cytosol of cells treated with farnesyltransferase inhibitors . AACR annual meeting, Washington, DC, 1996.

36. Vogt, A., Qian, Y., Hamilton, A.D., and Sebti, S.M., Burkitt Lymphoma Daudi cells contain two distinct

Curriculum Vitae Name and Title

Revision Date Page 10

farnesyltransferases with different sensitivities toward Ras CAAX peptidomimetics. AACR annual meeting, Toronto, 1995.

37. McGuire, T.F., Qian, Y., Blaskovich, M.A., Wathen, S.P., Marlowe, T., Vogt, A., Fossum, R.D., Corey, S.J., Hamilton, A.D. and Sebti, S.M., Farnesyltransferase inhibitors disrupt PDGF signaling events upstream as well as downstream of Ras. AACR annual meeting, Toronto, 1995.

38. Vogt, A., Qian Y., Blaskovich, M.A., Hamilton, A.D., Sebti, S.M., Design und Entwicklung von selektiven, nicht-peptidischen Farnesyltransferase-Inhibitoren als potentielle Antikrebsmittel. Annual Meeting of the German Pharmaceutical Society (DPhG) (1995)

4. Other publications and Invited talks 1. CNT as an enabling technology for zebrafish drug discovery. 4th international Definiens symposium,

Boston, MA (2013) 2. High-content screening for small molecule inhibitors of HIV Nef. Cambridge Healthtech Institute high-

content analysis conference, San Francisco, CA (2013) 3. HTS development and validation of the ORISTM Pro 384 cell migration assay. Innovative Molecular

Analysis Technologies Principal Investigators Meeting, Houston, TX November 2012 4. HCA of kidney development in transgenic zebrafish. Cambridge Healthtech Institute high-content

analysis conference, San Francisco, CA (2012) 5. Discovery of inhibitors of mitogen-activated protein kinase phosphatases using transgenic zebrafish.

University of Arizona, Department of Cellular and Molecular Medicine, Tucson, AZ (2011) 6. Imaging and quantification of zebrafish transgenes by automated confocal microscopy. 5th Australian

High Content Imaging Meeting, Walter and Eliza Hall Institute of Medical Research , Melbourne, Australia (2011)

7. High-content screening for inducers of autophagy. Cambridge Healthtech Institute high-content analysis conference, San Francisco, CA (2011)

8. Automating image acquisition and analysis of multicellular organisms. LabAutomation 2011, Society for Laboratory Automation and Screening, Palm Springs, CA (2011)

9. High-content analysis of zebrafish embryos in early stage drug discovery, Bio Conference Live, Online live event, www.bioconferencelive.com (2010)

10. Quantitation of fibroblast growth factor (FGF) signaling by high-content analysis in transgenic zebrafish. Cambridge Healthtech Institute high-content analysis conference, San Francisco, CA (2010)

11. Automated phenotyping of zebrafish embyos by high-content analysis. Cambridge Healthtech Institute high-content analysis conference, San Francisco, CA (2009)

12. Automated analysis of transgenic fluorescent zebrafish embryos by Cognition Network Technology. 8th International Meeting on Zebrafish Development & Genetics, Madison, WI (2008)

13. High-content analysis of zebrafish angiogenesis by Cognition Network Technology. Cambridge Healthtech Institute high-content analysis conference, San Francisco, CA (2008)

14. Applications of high-content analysis in zebrafish. PharmaDiscovery, Maryland (2006) 15. Finding content in high-content data: Two case studies for target-specific and phenotypic cell-based

assays. Cambridge Healthtech Institute high-content analysis conference, San Francisco, CA 2006 16. Discovery of a cell-active inhibitor of mitogen-activated protein kinase phosphatase-1 (MKP-1) by a high-

content screen and an unbiased statistical approach to hit selection. Cambridge Healthtech Institute high-content analysis conference, San Francisco, CA 2005

_______________________________________________________________

Curriculum Vitae Name and Title

Revision Date Page 11

PROFESSIONAL ACTIVITIES TEACHING: Provide a summary of courses and tutorials taught (include numbers and types of students taught, contact hours, number of lectures, etc), other lectures and seminars given, theses completed under your direction, service on Ph.D. committees, supervision of pre- and post-doctoral students, house staff physicians and fellows (clinical and research), specialty board memberships, continuing medical education activities. Institute of Pharmaceutical Chemistry, University of Hamburg, Germany Instructor, Instrumental Analysis and Organic/Drug Synthesis (1986 – 1990) Department of Pharmacology & Chemical Biology, University of Pittsburgh Medical Pharmacology Course - Cellular and Pathologic Basis of Disease, MSII medical students

Facilitator, Problem Based Learning Sessions and Conferences (1996 – 2006)

MED5133 – Neuroscience, MSII medical students (2007 – 2011) Facilitator, Adrenergic Pharmacology Workshop

MED5224 – Medical Pharmacology MSII, first year medical students (2008 – 2011)

Facilitator, Cell Signaling/Pharmacology Workshop

MSMPHL 2370 - Principles of Drug Discovery, graduate students (2004 - 2009). Lecture Topics: Cell-based assays, High-content screening, Animal models for screening

MSMPHL 2360 - Biology of Signal Transduction, graduate students (2003 – 2011)

Lecture Topics: Signaling and Drug Discovery MSMPHL 3360 – Molecular Pharmacology, graduate students (2010 - 2012)

Lecture Topics: Antibacterial and Antifungal Drugs MSMPHL 2310 – Principles of Pharmacology, graduate students (2011)

Lecture Topics: Principles of Drug Discovery MSMPHL 2370 – Drug Discovery Course

Lecture Topics : Phenotypic Discovery: Experimental Organisms (2012) Department of Computational and Systems Biology, University of Pittsburgh MSMPHL 2370 – Drug Discovery (2012) Lecture topics : Small organism discovery INTBP 3240 – Graduate student writing seminar (2013)

Mentor, Pittsburgh Public Schools’ SciTech Executive Experience (2012-2013)

Lecturer, TecBio joint Pitt/CMU program (2014)

Curriculum Vitae Name and Title

Revision Date Page 12

Mentor and Lecturer, Drug Discovery and Computational Biology (DisCoBio) program (2014)

Thesis Committee Service Ph.D. Thesis Committee, Peter McDonald, Pharmacology and Chemical Biology, Advisor : John Lazo (2007) M.S. Thesis Committee Member, Wan-Chen Lo, Department of Biostatistics, GSPH , Advisor: Roger Day (2008) Ph.D. Comprehensive Exam Committee, David Wheeler, Pharmacology and Chemical Biology, Advisor : Guillermo Romero (2009)

Curriculum Vitae Name and Title

Revision Date Page 13

OTHER RESEARCH RELATED AND ADMINISTRATIVE ACTIVITIES Guest Editor Pharmaceutics, Special issue “Drug Discovery Tools”, 2010-2011 Study Sections

Congressionally-directed peer-reviewed medicinal research program, US Army Research and Materiel Command (USAMRMC), 2001 Special Emphasis Panel/Scientific Review Group ZCA1 SRLB-D (C1) B, Small Business Innovative Research (SBIR) solicitation for Development of Anticancer Agents, NCI Developmental Therapeutics Program (2011) Special Emphasis Panel/Scientific Review Group Neurogenesis and Cell Fate Study Section [NCF] (2012) Small Business: Cancer Drug Development & Therapeutics ZRG1 OTC-T (10) B, (2012- 2013) Small Business: Chemistry, Biochemistry, Biophysics & Drug Discovery ZRG1 IMST-G (10) B (2014) Small Business: Cancer Drug Developments & Therapeutics ZRG1 OTC-T (12) B (2014), Co-Chair

Outside expert reviewer North Carolina Biotechnology Center Research Grant Program, 2009 Medical Research Council, UK, Research Grant Program, 2009 National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), UK, 2010 Clinical and Translational Science Institute (CTSI), University of Pittsburgh, Basic to Clinical Collaborative Research Pilot Program (BaCCoR), 2011 Netherlands Organization for Health Research and Development, Medium Investment Subsidy Programme (ZonMw), 2011

Invited Journal Referee,

Science, Cancer Research, Clinical Cancer Research, Oncogene, Molecular Pharmacology, Journal of Pharmacology and Experimental Therapeutics, Molecular Cancer Therapeutics, Cancer Chemotherapy and Pharmacology, FASEB Journal, Cell Biology International, Cell Cycle, Apoptosis, Biochemical Pharmacology, ChemMedChem, ACS Medicinal Chemistry Letters, BioTechniques, Toxicology in Vitro

Subject Matter Expert

USAMRMC Breast Cancer Knowledge Harvest Project, 1999-2000 Member, Governor Ridge’s Biotechnology Advisory Panel, 1999

Curriculum Vitae Name and Title

Revision Date Page 14

RESEARCH: Phenotypic drug discovery and Quantitative Systems Pharmacology. Molecular and cellular mechanisms of anti and pro-proliferative drug action for antineoplastic and regenerative medicine. Mitogen activated protein kinase phosphatases (MKPs) as molecular targets in tumor stress, metastasis, and myocardial ischemia. High-content, cell-based and whole organism screening as drug discovery tools for elusive targets. Development of image analysis methods emulating human cognitive processes for automated analysis of complex phenotypes. Establishment of infrastructure for automated imaging, analysis, and drug screening in zebrafish.

Role in Project Grant Number and Years Source

(Funded) Grant Title Percentage of Effort Inclusive $ Amount ACTIVE 1. NIH R01 HD053287 “Small Molecule Screens to Identify Probe Sets for the Study of Repair and

regeneration” (MPI: Hukriede, Vogt, Tsang), MPI, 15% effort, 2012-2017, $ $57,244 ADC 2. American Heart Association 13GRNT16830049 “Enhancing ALK1 expression as an approach to

hereditary hemorrhagic telangiectasia therapeutics” (PI: Roman), Co-investigator, 10% effort, $14,891 ADC

3. NIH R01 AI57083 “Small molecule inhibitors of HIV Nef signaling” (PI: Smithgall), Co-investigator, 20% effort, 2010 – 2015, $ 40,936 ADC

4. NIH S10 RR033452 “InCell 6000 High Content Instrument for Cellular Systems Biology Program” (PI: Taylor). Investigator, concurrent effort, Subproject “High resolution automated imaging and analysis of the embryonic zebrafish kidney tubules “

PENDING 1. NIH R01 CA172030 “Zebrafish HCS/HTS for inhibitors of mitogen-activated protein kinase

phosphatases” (PI : Vogt) 25% effort, 2015-2018, $ 110,000 ADC (impact score: 33, 26th percentile) 2. Department of Defense Breakthrough Award Level 2 ““Pharmacological strategies involving profilin for

metastatic breast cancer” (Pi : Roy), Co-investigator, 20% effort, 2015-2019, $ 86,795 ADC 3. NIH R21 application “Pharmacological approach to induce metastatic dormancy in breast cancer” (MPI :

Roy/Vogt), 15% effort, 2015-2017, $68,750 ADC 4. NIH R01 application “Cytoskeleton-Centric Drug Discovery for Angiogenesis Application” (PI: Roy) 12.5% effort, 2014-2019, $ 46,689 ADC PENDING RESUBMISSION 1. BCRP Breakthrough (BC131499) “Comprehensive Program for Breast Cancer Metastasis Treatment

and Therapeutic Development” (PI : Lee) 20% effort, 2014-2019 $391,998 ADC 2. NIH R24 application “Therapeutic Amelioration of Chronic Kidney Disease After Acute Kidney Injury” (PI:

Hukriede) 20% effort, 2014-2019, $150,000 ADC

COMPLETED 1. NIH RC4 DK090770 “Small Molecule Mediated Augmentation of Kidney Regeneration” (PI:

Hukriede), Co-Investigator, 20% effort, 2010-2013, $ 41,434 ADC

Curriculum Vitae Name and Title

Revision Date Page 15

2. NIH R44 GM090386 (SBIR Phase II) “High Throughput cell invasion assay amenable to high content imaging” (PI: Hulkower), Co-investigator, 10% effort, 2010-2014, $21,230 ADC

3. U Pitt Institute of Aging pilot grant “Zebrafish Parkinson’s disease models for drug discovery and evaluation of the role of aging in pathogenesis” (PI: Burton), Co-investigator, 5% effort, 2012-2013, $5,500 TDC

4. NIH R21 CA147985 “Transformative HTS cell migration assay for rapid screening of cancer therapeutics” (MPI : Vogt/Acharya), MPI 10% effort, 2010-2013, $ 79,188 ADC

5. NIH R01 HD053287, “Utilizing Small Molecule Screens to Delineate Embryonic Signaling Mechanisms” (PI : Hukriede) co- investigator, 10% effort, 2007-2012, $ 20,998 ADC

6. NIH P01 CA78039 Combinatorial approaches for novel anticancer agents (PI : Lazo) Director, Bioinformatics and Cell-based assay Core, 20% effort, 2005-2011, $174,203 ADC

7. NIH R01 AG026389 “Regulation of Autophagy in Dopaminergic Cell Death” (PI: Chu). Co-investigator, 10% effort, (2009-2011), $ 38,164 ADC

8. NIH R01 CA120792-01 Chemical Approaches for the Discovery of New Cancer Therapeutic Targets (PI : Koide). Investigator, 3.5% effort, (2006-2010), $ 16,757 ADC

9. NIH U54 MH074411-01 Pittsburgh Molecular Libraries Screening Center (PI: Lazo) Leader, HTS Core (2005), member (2006-2010), 15% effort, $390,798 ADC

10. NIH U19 CA52995 (NCDDG) Cancer Drugs Active Against Stress Signaling Pathways (PI: Powis/ Lazo). Investigator, 7.5% effort, 2005-2009, $100,292 ADC.

11. NIH R21 NS057026 High Throughput/Content Screens for Dynein Inhibitors (PI : Day), co-investigator, concurrent, 2006-2007, $ 3,272 ADC

12. NIH R03 MH081275 HTS for microtubule stabilizers (PI: Day), Consultant, concurrent, 2007-2008 13. NIH R03 MH083154 High-content cell-based screening for modulators of autophagy (PI: Yin/Vogt),

2007-2008 14. Pittsburgh Tissue Engineering Initiative, Inc., seed grant, “Use of High-Throughput Cell-Based Assays

to Discover small Molecule Growth Stimulators”, Principal Investigator, 30% effort, 2000-2001, $50,000 TDC

15. American Cancer Society George Heckman Institutional Award IRG-60-002-40 “Phosphatidic Acid Signaling in Oncogenesis”, Principal Investigator, 2000-2001, $7,500 TDC

16. Ben Franklin Technology Center of Western Pennsylvania Challenge Grant, Novel Cancer-Specific Chemotherapeutics. Project Director, 10% effort, 1999 – 2000, $100,000 TDC

17. SBIR phase 1 grant 1 R43 78003, National Cancer Institute (1998) Novel Bioreductively Activated Alkylating Agents, Principal Investigator, 20% effort, 1998 – 2000, $100,000 TDC

18. Ben Franklin Technology Center of Western Pennsylvania Challenge Grant (1998) Novel Cancer-Specific Chemotherapeutics. Project Director, 10% effort, 1998 – 1999, $100,000 TDC

19. SBIR phase 1 grant 1 R43 CA75923, National Cancer Institute, Novel Disulfide Antitumor Agents, Principal Investigator, 60% effort, 1997 – 1999, $100,000 TDC

20. Pittsburgh Tissue Engineering Initiative, Inc., seed grant “Inhibitors of Mitogen-activated Protein Kinase Phosphatase-1 as Growth Factor Mimics Designed for Use in Tissue Engineering”, Principal Investigator, 30% effort, 1996 - 1997, $20,000 TDC

SERVICE : Representative, School of Medicine, Chemical Hygiene Officers Committee, University of Pittsburgh,

2004-present

Member, University of Pittsburgh Cancer Institute, Cancer Therapeutics Program 2008 – present Member, School of Medicine Ambassadors program

Curriculum Vitae Name and Title

Revision Date Page 16

2009 – present Member, UPCI Cytometry Committee 2011 - present